Copper Histidinate Treatment for Menkes Disease
Approved for marketing · NCT04074512
Conditions: Menkes Disease
At a glance
- Research payments reported, 2025
- $104,089
- U.S. investigators named
- 5
- Sites paid
- 5
About the trial
- Sponsor
- Sentynl Therapeutics, Inc.
- Tested
- copper histidinate (drug)
- Results posted
- Not yet
This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.
From ClinicalTrials.gov, last updated 2026-03-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sentynl Therapeutics, Inc. reported $104,089 in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jasmine L. Knoll, M.D. Medical Genetics · Phoenix, AZ
- Tatachar Priyamvada, M.D. Pediatrics · Miami, FL
- Amy R. Calhoun, MD Medical Genetics · Iowa City, IA
- Dwight D. Koeberl Pediatrics · Durham, NC
- Kim Choong Wen Ng, MD Medical Genetics · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.